{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:36:49Z","timestamp":1790836609963,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"EU","award":["FP7-602825 ASKLEPIOS"],"award-info":[{"award-number":["FP7-602825 ASKLEPIOS"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2018.05.066","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T20:07:40Z","timestamp":1527192460000},"page":"4724-4735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin"],"prefix":"10.1016","volume":"37","author":[{"given":"Andr\u00e1s","family":"Marosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Dufkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Forr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"Felde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e1roly","family":"Erd\u00e9lyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"\u0160irmarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Palus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e1clav","family":"H\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Sal\u00e1t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"Tikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Gyuranecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"R\u016f\u017eek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Martina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Koraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.M.E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Bakonyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.066_b0005","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(13)62707-5","article-title":"Current status of rabies and prospects for elimination","volume":"384","author":"Fooks","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.066_b0010","doi-asserted-by":"crossref","first-page":"e2375","DOI":"10.1371\/journal.pntd.0002375","article-title":"Presence of virus neutralizing antibodies in cerebral spinal fluid correlates with non-lethal rabies in dogs","volume":"7","author":"Gnanadurai","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.05.066_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2014.02.013","article-title":"Survival from rabies encephalitis","volume":"339","author":"De Souza","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.vaccine.2018.05.066_b0020","first-page":"66","article-title":"A case of human survival of rabies, South Africa","volume":"31","author":"Weyer","year":"2016","journal-title":"South Afr J Inf Dis"},{"key":"10.1016\/j.vaccine.2018.05.066_b0025","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1474-4422(13)70038-3","article-title":"Human rabies: neuropathogenesis, diagnosis, and management","volume":"12","author":"Hemachudha","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virusres.2012.12.011","article-title":"Pathobiology of rabies virus and the European bat lyssaviruses in experimentally infected mice","volume":"172","author":"Healy","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.05.066_b0035","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s00705-017-3484-0","article-title":"Immunological aspects of rabies: a literature review","volume":"162","author":"Katz","year":"2017","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0040","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1128\/JVI.00302-11","article-title":"Ambivalent role of the innate immune response in rabies virus pathogenesis","volume":"85","author":"Chopy","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.micpath.2017.09.044","article-title":"Inhibition of MEK-ERK1\/2-MAP kinase signalling pathway reduces rabies virus induced pathologies in mouse model","volume":"112","author":"Manjunatha","year":"2017","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2018.05.066_b0050","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1128\/JVI.79.18.11801-11812.2005","article-title":"Rabies virus-induced activation of mitogen-activated protein kinase and NF-kappaB signaling pathways regulates expression of CXC and CC chemokine ligands in microglia","volume":"79","author":"Nakamichi","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2217\/17460794.3.5.481","article-title":"Concepts in the pathogenesis of rabies","volume":"3","author":"Dietzschold","year":"2008","journal-title":"Future Virol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0060","doi-asserted-by":"crossref","first-page":"17012","DOI":"10.1038\/cddiscovery.2017.12","article-title":"Impact of caspase-1\/11, -3, -7, or IL-1\u03b2\/IL-18 deficiency on rabies virus-induced macrophage cell death and onset of disease","volume":"3","author":"Kip","year":"2017","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.vaccine.2018.05.066_b0065","first-page":"163","article-title":"Exogenous interferon prolongs survival of rabies infected mice","volume":"26","author":"Mehta","year":"2015","journal-title":"Virus Dis"},{"issue":"33","key":"10.1016\/j.vaccine.2018.05.066_b0070","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1016\/j.vaccine.2018.01.082","article-title":"Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication","volume":"37","author":"Marosi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.066_b0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2014.02.012","article-title":"Recovery from rabies: a call to arms","volume":"339","author":"Jackson","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.vaccine.2018.05.066_b0080","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nmeth.1518","article-title":"Efficient CNS gene delivery by intravenous injection","volume":"7","author":"Louboutin","year":"2010","journal-title":"Nat Methods"},{"key":"10.1016\/j.vaccine.2018.05.066_b0085","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3727\/096368914X678337","article-title":"Mannitol-enhanced delivery of stem cells and their growth factors across the blood-brain barrier","volume":"23","author":"Gonzales-Portillo","year":"2014","journal-title":"Cell Transplant"},{"key":"10.1016\/j.vaccine.2018.05.066_b0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13365-011-0041-6","article-title":"The type I interferon response bridles rabies virus infection and reduces pathogenicity","volume":"17","author":"Chopy","year":"2011","journal-title":"J Neurovirol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0095","first-page":"2","article-title":"Ribavirin has an in vitro antiviral effect in rabies virus infected neuronal cells but fails to provide benefit in experimental rabies in mice","volume":"2","author":"Appolinario","year":"2013","journal-title":"J Virol Antivir Res"},{"key":"10.1016\/j.vaccine.2018.05.066_b0100","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.066_b0105","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1128\/JVI.00710-07","article-title":"Lethal silver-haired bat rabies virus infection can be prevented by opening the blood-brain barrier","volume":"81","author":"Roy","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0110","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1073\/pnas.93.11.5653","article-title":"Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America","volume":"93","author":"Morimoto","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.05.066_b0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2014.07.013","article-title":"Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice","volume":"110","author":"Huang","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.05.066_b0120","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7883\/yoken.64.463","article-title":"Gene expression analysis of host innate immune responses in the central nervous system following lethal CVS-11 infection in mice","volume":"64","author":"Sugiura","year":"2011","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.066_b0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1292\/jvms.68.589","article-title":"The histopathogenesis of paralytic rabies in six-week-old C57BL\/6J mice following inoculation of the CVS-11 strain into the right triceps surae muscle","volume":"68","author":"Park","year":"2006","journal-title":"J Vet Med Sci"},{"key":"10.1016\/j.vaccine.2018.05.066_b0130","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1128\/JVI.06699-11","article-title":"Postexposure treatment with the live-attenuated rabies virus (RV) vaccine TriGAS triggers the clearance of wild-type RV from the central nervous system (CNS) through the rapid induction of genes relevant to adaptive immunity in CNS tissues","volume":"86","author":"Li","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0135","doi-asserted-by":"crossref","first-page":"11533","DOI":"10.1128\/JVI.00615-12","article-title":"Protective vaccine-induced CD4+ T cell-independent B cell responses against rabies infection","volume":"86","author":"Dorfmeier","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0140","doi-asserted-by":"crossref","first-page":"e2614","DOI":"10.1371\/journal.pntd.0002614","article-title":"Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a guinea pig model of argentine hemorrhagic fever","volume":"7","author":"Gowen","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2018.05.066_b0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2015.12.006","article-title":"Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses","volume":"126","author":"Westover","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.05.066_b0150","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.05.066_b0155","doi-asserted-by":"crossref","first-page":"529151","DOI":"10.1100\/2012\/529151","article-title":"Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors","volume":"2012","author":"Fendrich","year":"2012","journal-title":"Sci World J"},{"key":"10.1016\/j.vaccine.2018.05.066_b0160","doi-asserted-by":"crossref","first-page":"e1030","DOI":"10.1038\/cddis.2013.557","article-title":"Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo","volume":"5","author":"Sonntag","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.vaccine.2018.05.066_b0165","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1128\/JCM.43.6.2786-2792.2005","article-title":"Development of a real-time, TaqMan reverse transcription-PCR assay for detection and differentiation of lyssavirus genotypes 1, 5, and 6","volume":"43","author":"Wakeley","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0170","unstructured":"World Organization for Animal Health (OIE). Rabies. In: Manual of diagnostic tests and vaccines for terrestrial animals. Paris, France; 2013. <http:\/\/www.oie.int\/en\/international-standard-setting\/terrestrial-manual\/access-online> [Accessed 17.07.17]."},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.066_b0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2013.01.003","article-title":"Current and future approaches to the therapy of human rabies","volume":"99","author":"Jackson","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.05.066_b0180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00705-016-3081-7","article-title":"Comparison of immune responses to attenuated rabies virus and street virus in mouse brain","volume":"162","author":"Miao","year":"2016","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0185","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.4161\/hv.25431","article-title":"Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies: results of In vitro and In vivo studies","volume":"9","author":"Madhusudana","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"10.1016\/j.vaccine.2018.05.066_b0190","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1016\/j.vaccine.2017.12.028","article-title":"Mannitol treatment is not effective in therapy of rabies virus infection in mice","volume":"37","author":"Dufkova","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.066_b0195","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1038\/ncomms4864","article-title":"Pathogenic potential of interferon \u03b1\u03b2 in acute influenza infection","volume":"5","author":"Davidson","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2018.05.066_b0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s002620050356","article-title":"Markedly induced asialoGM1+CD8+ T cell production and enhancement of antimetastatic activity by interferon \u03b2 with folic or folinic acid","volume":"44","author":"Iigo","year":"1997","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2018.05.066_b0205","doi-asserted-by":"crossref","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"1","author":"Oestereich","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"33","key":"10.1016\/j.vaccine.2018.05.066_b0210","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1016\/j.vaccine.2018.04.003","article-title":"The effect of combined drugs therapy on the course of clinical rabies infection in a murine model","volume":"37","author":"Smreczak","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.066_b0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13550280701883857","article-title":"Furious and paralytic rabies of canine origin: neuroimaging with virological and cytokine studies","volume":"14","author":"Laothamatas","year":"2008","journal-title":"J Neurovirol"},{"key":"10.1016\/j.vaccine.2018.05.066_b0220","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3389\/fmicb.2018.00397","article-title":"Analysis of mouse brain transcriptome after experimental duvenhage virus infection shows activation of innate immune response and pyroptotic cell death pathway","volume":"9","author":"Koraka","year":"2018","journal-title":"Front Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:53Z","timestamp":1759401233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":44,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X18307060"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.066","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}